{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:59Z","timestamp":1791245219274,"version":"4.1.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"16","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,27]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) can develop hypogammaglobulinemia, a form of secondary immune deficiency (SID), from the disease and treatments. Patients with hypogammaglobulinemia with recurrent infections may benefit from immunoglobulin replacement therapy (IgRT). This study evaluated patterns of immunoglobulin G (IgG) testing and the effectiveness of IgRT in real-world patients with CLL or NHL. A retrospective, longitudinal study was conducted among adult patients diagnosed with CLL or NHL. Clinical data from the Massachusetts General Brigham Research Patient Data Registry were used. IgG testing, infections, and antimicrobial use were compared before vs 3, 6, and 12\u00a0months after IgRT initiation. Generalized estimating equation logistic regression models were used to estimate odds ratios, 95% confidence intervals, and P values. The study population included 17\u2009192 patients (CLL: n\u00a0=\u00a03960; median age, 68 years; NHL: n\u00a0=\u00a013\u2009232; median age, 64 years). In the CLL and NHL cohorts, 67% and 51.2% had IgG testing, and 6.5% and 4.7% received IgRT, respectively. After IgRT initiation, the proportion of patients with hypogammaglobulinemia, the odds of infections or severe infections, and associated antimicrobial use, decreased significantly. Increased frequency of IgG testing was associated with a significantly lower likelihood of severe infection. In conclusion, in real-world patients with CLL or NHL, IgRT was associated with significant reductions in hypogammaglobulinemia, infections, severe infections, and associated antimicrobials. Optimizing IgG testing and IgRT are warranted for the comprehensive management of SID in patients with CLL or NHL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013073","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T13:51:36Z","timestamp":1718977896000},"page":"4239-4249","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3062-6819","authenticated-orcid":false,"given":"Jacob D.","family":"Soumerai","sequence":"first","affiliation":[{"name":"1Center for Lymphoma, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4618-2108","authenticated-orcid":false,"given":"Zaid","family":"Yousif","sequence":"additional","affiliation":[{"name":"2Takeda Pharmaceuticals USA, Inc, Lexington, MA"},{"name":"3Division of Clinical Pharmacy, University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5263-1283","authenticated-orcid":false,"given":"Thais","family":"Gift","sequence":"additional","affiliation":[{"name":"2Takeda Pharmaceuticals USA, Inc, Lexington, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Desai","sequence":"additional","affiliation":[{"name":"4Analysis Group, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Huynh","sequence":"additional","affiliation":[{"name":"4Analysis Group, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchen","family":"Ye","sequence":"additional","affiliation":[{"name":"4Analysis Group, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3464-4897","authenticated-orcid":false,"given":"Azeem","family":"Banatwala","sequence":"additional","affiliation":[{"name":"4Analysis Group, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Clear","sequence":"additional","affiliation":[{"name":"4Analysis Group, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Pinaire","sequence":"additional","affiliation":[{"name":"4Analysis Group, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Belsky","sequence":"additional","affiliation":[{"name":"5Mass General Brigham, Research Information Science and Computing, Somerville, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichuan Grace","family":"Hsieh","sequence":"additional","affiliation":[{"name":"5Mass General Brigham, Research Information Science and Computing, Somerville, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Herrick","sequence":"additional","affiliation":[{"name":"5Mass General Brigham, Research Information Science and Computing, Somerville, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli P.","family":"Darnell","sequence":"additional","affiliation":[{"name":"1Center for Lymphoma, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA"},{"name":"6Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[{"name":"4Analysis Group, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Sanchirico","sequence":"additional","affiliation":[{"name":"2Takeda Pharmaceuticals USA, Inc, Lexington, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn N.","family":"Murphy","sequence":"additional","affiliation":[{"name":"7Neurology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"2024082712512334800_bib1","doi-asserted-by":"crossref","first-page":"738915","DOI":"10.3389\/fimmu.2021.738915","article-title":"Secondary immunodeficiency in hematological malignancies: focus on multiple myeloma and chronic lymphocytic leukemia","volume":"12","author":"Allegra","year":"2021","journal-title":"Front Immunol"},{"key":"2024082712512334800_bib2","doi-asserted-by":"crossref","first-page":"1098326","DOI":"10.3389\/fonc.2023.1098326","article-title":"Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: a systematic literature review","volume":"13","author":"Jolles","year":"2023","journal-title":"Front Oncol"},{"key":"2024082712512334800_bib3","doi-asserted-by":"crossref","first-page":"1062376","DOI":"10.3389\/fimmu.2023.1062376","article-title":"Should treatment of hypogammaglobulinemia with immunoglobulin replacement therapy (IgRT) become standard of care in patients with chronic lymphocytic leukemia?","volume":"14","author":"Noto","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"2024082712512334800_bib4","doi-asserted-by":"crossref","first-page":"e2012070","DOI":"10.4084\/mjhid.2012.070","article-title":"Infectious complications in chronic lymphocytic leukemia","volume":"4","author":"Nosari","year":"2012","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"6","key":"2024082712512334800_bib5","first-page":"374","article-title":"Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up","volume":"78","author":"Molica","year":"1993","journal-title":"Haematologica"},{"key":"2024082712512334800_bib6","unstructured":"Infection Control in Patients With CLL May Be Pivotal for Survival Outcomes\n          . Targeted Oncology. 2021. Accessed 1 March 2024. https:\/\/www.targetedonc.com\/view\/infection-control-in-patients-with-cll-may-be-pivotal-for-survival-outcomes."},{"issue":"6","key":"2024082712512334800_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.blre.2018.04.007","article-title":"Infections in patients with chronic lymphocytic leukaemia: mitigating risk in the era of targeted therapies","volume":"32","author":"Teh","year":"2018","journal-title":"Blood Rev"},{"issue":"6","key":"2024082712512334800_bib8","doi-asserted-by":"crossref","first-page":"622","DOI":"10.6004\/jnccn.2022.0031","article-title":"NCCN Guidelines\u00ae Insights: chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 3.2022: featured updates to the NCCN Guidelines","volume":"20","author":"Wierda","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"2024082712512334800_bib9","unstructured":"Clinical Practice Guidelines \u2013 Chronic Lymphocytic Leukaemia\n          . ESMO. Accessed 1 March 2024. https:\/\/www.esmo.org\/guidelines\/guidelines-by-topic\/esmo-clinical-practice-guidelines-haematological-malignancies\/chronic-lymphocytic-leukaemia."},{"issue":"5","key":"2024082712512334800_bib10","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"2024082712512334800_bib11","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3389\/fimmu.2014.00626","article-title":"Immunoglobulin replacement therapy in secondary hypogammaglobulinemia","volume":"5","author":"Compagno","year":"2014","journal-title":"Front Immunol"},{"issue":"2","key":"2024082712512334800_bib12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2024082712512334800_bib13","doi-asserted-by":"crossref","first-page":"103896","DOI":"10.1016\/j.critrevonc.2022.103896","article-title":"Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology","volume":"181","author":"Shah","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"2024082712512334800_bib14","unstructured":"Research Patient Data Registry\n          . Mass General Brigham RISC. Accessed 1 March 2024. https:\/\/rc.partners.org\/about\/who-we-are-risc\/research-patient-data-registry."},{"issue":"12","key":"2024082712512334800_bib15","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute\u2013Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"suppl 1","key":"2024082712512334800_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-137094","article-title":"Real-world IgG testing frequency and characteristics associated with hypogammaglobulinemia after anti-CD20 exposure in patients with chronic lymphocytic leukemia (CLL)","volume":"136","author":"Hooley","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2024082712512334800_bib17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/ejh.13223","article-title":"Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies","volume":"102","author":"Na","year":"2019","journal-title":"Eur J Haematol"},{"issue":"14","key":"2024082712512334800_bib18","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1080\/10428194.2021.1961233","article-title":"Infections in secondary immunodeficiency patients treated with Privigen\u00ae or Hizentra\u00ae: a retrospective US administrative claims study in patients with hematological malignancies","volume":"62","author":"Mallick","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"2024082712512334800_bib19","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2217\/imt-2022-0142","article-title":"Reduced risk of infections with the intravenous immunoglobulin, IgPro10, in patients at risk of secondary immunodeficiency-related infections","volume":"14","author":"Lahue","year":"2022","journal-title":"Immunotherapy"},{"key":"2024082712512334800_bib20","doi-asserted-by":"crossref","first-page":"108419","DOI":"10.1016\/j.clim.2020.108419","article-title":"Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): a retrospective multicenter study","volume":"215","author":"Legendre","year":"2020","journal-title":"Clin Immunol"},{"key":"2024082712512334800_bib21","doi-asserted-by":"crossref","first-page":"101020","DOI":"10.1016\/j.blre.2022.101020","article-title":"Secondary antibody deficiency in chronic lymphocytic leukemia and non-Hodgkin lymphoma: recommendations from an international expert panel","volume":"58","author":"Jolles","year":"2023","journal-title":"Blood Rev"},{"issue":"1","key":"2024082712512334800_bib22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2008.04.044","article-title":"Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection","volume":"122","author":"Bonagura","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"2024082712512334800_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","article-title":"Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies","volume":"137","author":"Orange","year":"2010","journal-title":"Clin Immunol"},{"issue":"3 suppl","key":"2024082712512334800_bib24","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2012.07.002","article-title":"Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology","volume":"130","author":"Orange","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"2024082712512334800_bib25","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.anai.2019.08.012","article-title":"Antibody deficiency testing for primary immunodeficiency: a practical review for the clinician","volume":"123","author":"Marsh","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2024082712512334800_bib26","first-page":"20499361211036773","article-title":"Infectious complications of CAR T-cell therapy: a clinical update","volume":"8","author":"Stewart","year":"2021","journal-title":"Ther Adv Infect Dis"},{"issue":"suppl 1","key":"2024082712512334800_bib27","doi-asserted-by":"crossref","first-page":"e14157","DOI":"10.1111\/tid.14157","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"2024082712512334800_bib28","doi-asserted-by":"crossref","first-page":"100596","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"},{"issue":"4","key":"2024082712512334800_bib29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/17474086.2022.2063833","article-title":"Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians","volume":"15","author":"Kampouri","year":"2022","journal-title":"Expert Rev Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/16\/4239\/2239661\/blooda_adv-2024-013073-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/16\/4239\/2239661\/blooda_adv-2024-013073-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T12:51:46Z","timestamp":1724763106000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/16\/4239\/516590\/IgG-testing-immunoglobulin-replacement-therapy-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":29,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013073","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]}}}